Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/nanopublications.trig#NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_assertion description "[Ruxolitinib is a small-molecule inhibitor�of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_assertion evidence source_evidence_literature NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_assertion SIO_000772 23307549 NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_assertion wasDerivedFrom befree-20140225 NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_assertion wasGeneratedBy ECO_0000203 NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.
- befree-20140225 importedOn "2014-02-25" NP718263.RAkJlGyQ_1Ll2hYEJIDZ87Gu4haDmtfHGPxkr2h14sUhg130_provenance.